Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused ...

Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.

The EC has approved Incyte’s Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory FL.

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...